Who
Richard J. Daly
President and CEO
Company insider
Files Form 4 as: President and CEO, Catalyst Pharmaceutical; Director, Opiant Pharmaceuticals; Chief Executive Officer, Palisade Bio; Director, Synergy Pharmaceuticals.
In numbers
- Trades disclosed
- 120
- Buys
- 8
- Sells
- 3
- Bought
- $115K
- Sold
- $2.5M
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 24 Jul 2015
- Last trade
- 15 Jul 2026
- Last filed
- 17 Jul 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 15 Jul 2026filed 17 Jul 2026 | Catalyst PharmaceuticalBiotechnology | SEC FORM 4 Code D | $8.5M271,266 at $31.50 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —40,013 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —115,283 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —33,500 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —33,500 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —30,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —20,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —1,365,319 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —491,160 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —381,948 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —126,316 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —40,013 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticalsoption or derivative | SEC FORM 4 Code D | —115,283 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —20,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —15,000 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —1,365,319 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —491,160 at $0.00 | filing |
| 15 Jul 2026filed 17 Jul 2026 | Catalyst Pharmaceuticaloption or derivative · Biotechnology | SEC FORM 4 Code D | —381,948 at $0.00 | filing |
News
Analyzing Indivior (NASDAQ:INDV) and Palisade Bio (NASDAQ:PALI)PALI · dailypolitical.com · 24 Oct 2026Critical Survey: Nexentis Technologies (NASDAQ:NXTS) versus Palisade Bio (NASDAQ:PALI)PALI · themarketsdaily.com · 24 Oct 2026Palisade Bio Rises 9% As PALI-2108 Shows Early Activity In Crohn's DiseasePALI · rttnews.com · 20 Oct 2026
0 headlines in the last 90 days name Richard J. Daly; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.